INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 12, 2018	Aug. 20, 2018	Dec. 31, 2022	Dec. 31, 2021
Naltrexone Implant Formulation [Member] \| Australia from Trinity Compound Solutions [Member]
Aggregate purchase price, value		$ 236,000
Patent acquired	$ 15,200
Estimated useful lives	13 years
Cash paid for acquisition		$ 10,000
Aggregate purchase price, Shares		20,000
Intellectual Property [Member]
Amortization expense			$ 0	$ 35,370
Estimated useful lives			5 years
Impairment loss			$ 141,480
Intellectual property, carrying value			0
Patents [Member]
Amortization expense			1,179	$ 1,180
Accumulated amortization			$ 4,994